Donald Trump signed an executive order on Dec. 18 to fast-track the Food and Drug Administration’s review to reclassify cannabis as a Schedule III substance under the Controlled Substances Act. Pot stocks Trulieve Cannabis, Curaleaf, Cresco Labs, Green Thumb Industries, and Canopy Growth plummeted by up to 39% due to the scope of Trump’s intentions.
Source: https://www.fool.com/investing/2025/12/22/trump-rescheduling…
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
This year has been good for bank stocks after a hiccup in April because of Donald Trump’s “Liberation Day” tariff plans. Since then, markets have rebounded strongly and reached record highs, supported by the Federal Reserve’s interest rate cuts.
After a weak performance since its stock market debut last year, success in the prediction markets could help drive a rebound for Webull. Robinhood Markets’ expansion into the prediction markets could help assuage concerns about future growth.
